|
186 Products |
| 186 Products |
|
1696 Diseases |  |
94663 News |  |
| «12...10341035103610371038103910401041104210431044...10631064» |
- | Farydak (panobinostat) / Secura Bio
Enrollment open, Combination therapy: Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients (clinicaltrials.gov) - Aug 19, 2013
P1/2, N=38, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting
- | dexamethasone sodium phosphate-loaded RBC (EDS-EP) / Erydel
New P1 trial: EryDex Pharmacokinetics in Healthy Volunteers (clinicaltrials.gov) - Aug 18, 2013
P1, N=18, Active, not recruiting, Sponsor: Erydel
- ||||||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Aug 18, 2013
P3, N=310, Completed, Sponsor: Amgen
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Korlym (mifepristone) / Corcept Therap
New P3 trial: Mifepristone in Children With Refractory Cushing's Disease (clinicaltrials.gov) - Aug 15, 2013
P3, N=20, Recruiting, Sponsor: Corcept Therapeutics
- | methylprednisolone acetate / Generic mfg.
Clinical: Intraarticular Platelet-rich Plasma Injections Versus Corticosteroid Injections in Primary Knee Osteoarthritis (clinicaltrials.gov) - Aug 14, 2013
P4, N=100, Recruiting, Sponsor: King Hamad University Hospital, Bahrain
- dexamethasone / Generic mfg.
Trial termination, Surgery: A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery (clinicaltrials.gov) - Aug 14, 2013
P1, N=8, Terminated, Sponsor: Allergan
Active, not recruiting --> Completed Suspended --> Terminated; Study terminated due to corporate decision.
- dexamethasone / Generic mfg.
Enrollment change, Surgery: A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery (clinicaltrials.gov) - Aug 14, 2013
P1, N=8, Terminated, Sponsor: Allergan
Suspended --> Terminated; Study terminated due to corporate decision. N=24 --> 8
- Ilaris (canakinumab) / Novartis
Trial withdrawal: Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease (clinicaltrials.gov) - Aug 13, 2013
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
N=24 --> 8 Not yet recruiting --> Withdrawn
- Ilaris (canakinumab) / Novartis
Enrollment change: Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease (clinicaltrials.gov) - Aug 13, 2013
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Withdrawn N=230 --> 0
- methylprednisolone acetate / Generic mfg.
Trial initiation date: Effectiveness of Caudal Epidural Injections in Treatment of Chronic Low Back and Lower Extremity Pain (clinicaltrials.gov) - Aug 13, 2013
P0, N=240, Completed, Sponsor: Pain Management Center of Paducah
N=230 --> 0 Initiation date: Jan 2006 --> Jan 2007
- triamcinolone acetonide / Generic mfg.
Trial completion, Surgery: Cataract Surgery With Intracameral Triamcinolone in Infants (clinicaltrials.gov) - Aug 12, 2013
P=N/A, N=60, Completed, Sponsor: Fundação Altino Ventura
Initiation date: Jan 2006 --> Jan 2007 Active, not recruiting --> Completed
- bortezomib / Generic mfg., dexamethasone / Generic mfg.
Enrollment change: Maintenance Therapy With Subcutaneous Bortezomib (clinicaltrials.gov) - Aug 12, 2013
P2, N=216, Not yet recruiting, Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
Active, not recruiting --> Completed N=154 --> 216
- | decernotinib (VX-509) / Vertex
Clinical: Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects (clinicaltrials.gov) - Aug 12, 2013
P1, N=28, Completed, Sponsor: Vertex Pharmaceuticals Incorporated
N=154 --> 216 Active, not recruiting --> Completed
- |||| Onbrez (indacaterol) / Novartis
Trial completion: Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent Asthma (clinicaltrials.gov) - Aug 11, 2013
P2, N=330, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | alisertib (MLN8237) / Puma
Trial initiation date, Combination therapy: Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer (clinicaltrials.gov) - Aug 11, 2013
P1/2, N=43, Recruiting, Sponsor: Thomas Jefferson University
Active, not recruiting --> Completed Initiation date: May 2013 --> Aug 2013
- Avastin (bevacizumab) / Roche, Oncaspar liquid (pegaspargase) / Servier
New P2 trial: Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma (clinicaltrials.gov) - Aug 11, 2013
P2, N=30, Recruiting, Sponsor: Sun Yat-sen University
- | alisertib (MLN8237) / Puma
Enrollment open, Combination therapy: Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer (clinicaltrials.gov) - Aug 11, 2013
P1/2, N=43, Recruiting, Sponsor: Thomas Jefferson University
Initiation date: May 2013 --> Aug 2013 Not yet recruiting --> Recruiting
- bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Enrollment open: RVD Lite: Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) (clinicaltrials.gov) - Aug 11, 2013
P2, N=50, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Dupixent (dupilumab) / Sanofi, Regeneron
New P2 trial: An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis (clinicaltrials.gov) - Aug 8, 2013
P2, N=56, Recruiting, Sponsor: Sanofi
- || dexamethasone / Generic mfg.
New P3 trial: DEXSAR: Low-dose Dexamethasone in Newly Diagnosed Pulmonary Sarcoidosis (clinicaltrials.gov) - Aug 8, 2013
P3, N=76, Recruiting, Sponsor: St. Antonius Hospital
- | New P2 trial: A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 8, 2013
P2, N=39, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- quisinostat (JNJ 26481585) / ChemRar, Viriom
Enrollment change, Combination therapy, Epigenetic controller: A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Aug 7, 2013
P1, N=18, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting N=40 --> 18
- ||||||| Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
Trial completion, Combination therapy: Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry. (clinicaltrials.gov) - Aug 7, 2013
P3, N=311, Completed, Sponsor: GlaxoSmithKline
N=40 --> 18 Active, not recruiting --> Completed
- | Oncaspar liquid (pegaspargase) / Servier
Trial completion: ALLR3: Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 7, 2013
P3, N=470, Completed, Sponsor: Children's Cancer and Leukaemia Group
Active, not recruiting --> Completed Recruiting --> Completed
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: HOVON-44: Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 7, 2013
P3, N=340, Completed, Sponsor: Commissie Voor Klinisch Toegepast Onderzoek
Recruiting --> Completed Recruiting --> Completed
- Avastin (bevacizumab) / Roche
New P2 trial: Efficiency Study for Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis With Bevasizumab (clinicaltrials.gov) - Aug 5, 2013
P2, N=30, Recruiting, Sponsor: Qingdao Central Hospital
- Avastin (bevacizumab) / Roche
Enrollment open: Efficiency Study for Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis With Bevasizumab (clinicaltrials.gov) - Aug 5, 2013
P2, N=30, Recruiting, Sponsor: Qingdao Central Hospital
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Riarify (beclometasone/formoterol/glycopyrrolate) / Chiesi
New P3 trial: Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD (clinicaltrials.gov) - Aug 4, 2013
P3, N=1863, Recruiting, Sponsor: Chiesi Farmaceutici S.p.A.
- dexamethasone / Generic mfg., ondansetron / Generic mfg.
Enrollment closed: VPOP2: Postoperative Vomiting in Children: Comparison Tri - Versus bi -Prophylaxis (clinicaltrials.gov) - Aug 1, 2013
P=N/A, N=322, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| budesonide/formoterol / Generic mfg.
Enrollment change: SECURE 1: Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Jul 31, 2013
P4, N=793, Completed, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting N=570 --> 793
- |||| budesonide/formoterol / Generic mfg.
Trial completion: SECURE 1: Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Jul 31, 2013
P4, N=793, Completed, Sponsor: AstraZeneca
N=570 --> 793 Active, not recruiting --> Completed
- saracatinib (AZD0530) / AstraZeneca
Trial termination: Saracatinib in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Jul 31, 2013
P2, N=32, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Per protocol, study was terminated due to low rate of randomized patients.
- | Decadron (dexamethasone) / Merck (MSD)
New P4 trial: ER11-02: Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients. (clinicaltrials.gov) - Jul 30, 2013
P4, N=323, Recruiting, Sponsor: Ottawa Hospital Research Institute
- | bortezomib / Generic mfg., dexamethasone / Generic mfg.
New P2 trial: Maintenance Therapy With Subcutaneous Bortezomib (clinicaltrials.gov) - Jul 30, 2013
P2, N=216, Not yet recruiting, Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
- clofarabine / Generic mfg.
Trial completion, Combination therapy: Vandevol: Safety of Clofarabine With Multiagent Chemotherapy in Childhood Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 29, 2013
P1, N=20, Completed, Sponsor: University Hospital, Lille
Active, not recruiting --> Terminated; Per protocol, study was terminated due to low rate of randomized patients. Active, not recruiting --> Completed
- ||||||| dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Trial completion: QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression (clinicaltrials.gov) - Jul 29, 2013
P3, N=120, Completed, Sponsor: PETHEMA Foundation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Riarify (beclometasone/formoterol/glycopyrrolate) / Chiesi
New P3 trial: Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Jul 28, 2013
P3, N=3686, Recruiting, Sponsor: Chiesi Farmaceutici S.p.A.
- Oncaspar liquid (pegaspargase) / Servier, Marqibo (vincristine liposomal) / Servier, Aurobindo
Clinical: Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 28, 2013
P2, N=11, Terminated, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Increased rate of bacterial infections
- Oncaspar liquid (pegaspargase) / Servier, Marqibo (vincristine liposomal) / Servier, Aurobindo
Clinical: Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 28, 2013
P2, N=11, Terminated, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Terminated; Increased rate of bacterial infections N=30 --> 11
- |||||||||| bortezomib / Generic mfg.
New P3 trial: OPTIMRETREAT: Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib (clinicaltrials.gov) - Jul 28, 2013
P3, N=240, Recruiting, Sponsor: Janssen-Cilag International NV
- dexamethasone / Generic mfg., lenalidomide / Generic mfg., carfilzomib / Generic mfg.
Clinical: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma (clinicaltrials.gov) - Jul 25, 2013
P2, N=30, Recruiting, Sponsor: National Cancer Institute (NCI)
N=30 --> 11 N=14 --> 30
- | dexamethasone / Generic mfg., cisplatin / Generic mfg.
New P2 trial: The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Jul 25, 2013
P2, N=92, Recruiting, Sponsor: Jiangsu Simcere Pharmaceutical R&D Co. Ltd.
- |||| Incruse Ellipta (umeclidinium) / GSK, Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
Trial completion, Combination therapy: Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma (clinicaltrials.gov) - Jul 24, 2013
P2, N=421, Completed, Sponsor: GlaxoSmithKline
N=14 --> 30 Recruiting --> Completed
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: COMRADE-B: Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO) (clinicaltrials.gov) - Jul 24, 2013
P3, N=244, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Recruiting --> Completed
- || Duaklir (aclidinium bromide/formoterol fumarate) / Covis Pharma
New P3 trial: Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Jul 23, 2013
P3, N=900, Recruiting, Sponsor: Almirall, S.A.
- ||| beclometasone/formoterol / Generic mfg., fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Trial completion, Combination therapy, Real-world evidence, Real-world effectiveness, Real-world: REACH: Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management (clinicaltrials.gov) - Jul 23, 2013
P=N/A, N=194723, Completed, Sponsor: Research in Real-Life Ltd
Recruiting --> Completed Not yet recruiting --> Completed
- fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
New P4 trial: Dose-Response of Salmeterol in Children (clinicaltrials.gov) - Jul 22, 2013
P4, N=10, Recruiting, Sponsor: University of Florida
- propranolol / Generic mfg.
Trial termination: Corticosteroids With Placebo Versus Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH) (clinicaltrials.gov) - Jul 21, 2013
P2, N=9, Terminated, Sponsor: Seattle Children's Hospital
Not yet recruiting --> Completed Active, not recruiting --> Terminated; Insufficient enrollment
- Ninlaro (ixazomib) / Takeda
Enrollment change: Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 21, 2013
P1, N=24, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Active, not recruiting --> Terminated; Insufficient enrollment N=15 --> 24
- propranolol / Generic mfg.
Enrollment change: Corticosteroids With Placebo Versus Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH) (clinicaltrials.gov) - Jul 21, 2013
P2, N=9, Terminated, Sponsor: Seattle Children's Hospital
N=15 --> 24 N=60 --> 9